Spencer Leroux

206-389-4541
SLeroux@fenwick.com
Associate
Corporate

Spencer
Leroux

Spencer
Leroux

Spencer
Leroux

Associate
Corporate

Spencer represents life sciences and technology companies on a variety of corporate matters, including capital markets, securities and public company advisory work, and corporate governance. Spencer has advised a wide range of publicly traded companies on all aspects of life as a public company. Spencer has also represented issuers in private placements, at-the-market offerings, and underwritten bond offerings and follow-on offerings, among other capital markets transactions.

Prior to joining Fenwick, Spencer was an associate in the capital markets and public company advisory group of a leading global law firm.

While in law school, Spencer was a judicial intern for the Honorable John A. Gibney, Jr. of the U.S. District Court for the Eastern District of Virginia and served as a lead articles editor for the William & Mary Law Review.

  • A clinical-stage pharmaceutical company in its go-public de-SPAC transaction
  • A late-stage clinical pharmaceutical company in a $225M secondary equity offering
  • A clinical-stage pharmaceutical company on the establishment of a $50M at-the-market equity offering program
  • A nuclear energy company on the refresh of its at-the-market equity offering program, including filing the company’s initial WKSI shelf registration
  • A leading multinational healthcare and insurance company in registered debt offerings totaling over $30B
  • A leading global technology company on the establishment of its $5B commercial paper program

  • A clinical-stage pharmaceutical company in its go-public de-SPAC transaction
  • A late-stage clinical pharmaceutical company in a $225M secondary equity offering
  • A clinical-stage pharmaceutical company on the establishment of a $50M at-the-market equity offering program
  • A nuclear energy company on the refresh of its at-the-market equity offering program, including filing the company’s initial WKSI shelf registration
  • A leading multinational healthcare and insurance company in registered debt offerings totaling over $30B
  • A leading global technology company on the establishment of its $5B commercial paper program